https://www.regulatoryrapporteur.org/industry-news/mhras-irp-pathway-now-open-for-new-medicines-approvals/519.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/ema/hma-publish-workplan-for-the-responsible-use-of-ai/520.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/non-hormonal-menopause-drug-approved-in-uk/521.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/artificial-intelligence/artificial-intelligence-in-drug-discovery/452.article 2024-05-22T15:22:38.310Z https://www.regulatoryrapporteur.org/biologics/innovating-and-harmonising-access-and-requirements-amid-the-global-regulatory-challenges-of-biologics/511.article 2024-02-23T08:51:01.570Z https://www.regulatoryrapporteur.org/biologics/cell-and-gene-therapy-navigating-complexities-in-cmc-development-for-optimisation-of-global-regulatory-strategies/512.article 2024-02-23T08:51:01.570Z https://www.regulatoryrapporteur.org/oncology/the-changing-face-of-oncology-development-is-cancer-still-different-a-us-perspective/513.article 2024-02-14T14:57:40.617Z https://www.regulatoryrapporteur.org/biologics/navigating-early-drug-development-investment-a-detailed-guide-to-due-diligence/514.article 2024-02-14T14:57:40.617Z https://www.regulatoryrapporteur.org/biologics/a-weight-of-evidence-approach-for-the-non-clinical-evaluation-of-complex-biologicals/515.article 2024-02-23T08:51:01.570Z https://www.regulatoryrapporteur.org/january-2024-contents/516.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/editorials/the-increasing-complexity-of-biological-medicinal-products/518.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/industry-news/3d-printed-device-could-reduce-need-for-animal-testing/527.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regrappod--january-2024/529.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/ema-set-to-host-psychedelics-uses-workshop-in-april/530.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-workplan-to-support-safe-access-to-medtech/542.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/scientists-hail-gram-negative-bacteria-killing-antibiotic/543.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/device-which-can-detect-skin-cancer-approved-by-fda/544.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-tightens-restrictions-on-fluoroquinolones/545.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/non-surgical-gastric-balloon-to-be-made-available-on-nhs/547.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/34m-nihr-funding-open-to-researchers-from-lmics-and-uk/549.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regrappod--in-conversation-with-topras-regops-spin/551.article 2025-02-06T14:15:33.007Z https://www.regulatoryrapporteur.org/industry-news/disposable-vapes-set-to-be-banned-in-britain-by-2025/552.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/aus-uk-joint-agency-vetmed-approval-process-agreed/553.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/medical-devices/eu-mdr-implementation-what-is-changing-for-the-medical-device-industry/532.article 2024-03-05T14:50:58.620Z https://www.regulatoryrapporteur.org/medical-devices/the-rise-of-femtech-and-why-compliance-is-key-to-its-success/533.article 2026-02-05T12:07:55.550Z https://www.regulatoryrapporteur.org/medical-devices/ai-meets-medtech-big-opportunities-require-a-measured-approach/534.article 2026-02-03T18:07:34.450Z https://www.regulatoryrapporteur.org/medical-devices/overview-of-medical-device-regulations-in-canada/535.article 2024-02-14T14:55:08.647Z https://www.regulatoryrapporteur.org/medical-devices/chemical-characterisation-a-critical-first-step-for-medical-device-development/536.article 2024-02-14T14:55:08.647Z https://www.regulatoryrapporteur.org/pharmaceuticals/china-drug-master-file-registration-pathways-and-requirements/537.article 2024-02-14T14:55:08.647Z https://www.regulatoryrapporteur.org/february-2024-contents/538.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/editorials/sink-or-swim-the-changing-tides-of-device-regulation/539.article 2024-04-30T14:55:37.537Z https://www.regulatoryrapporteur.org/commentary/developing-a-digital-people-strategy-to-harness-the-power-of-generative-ai/556.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/nhs-pharmacy-first-offers-an-alternative-to-gps-in-england/560.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/ema-platform-to-monitor-use-of-antimicrobials/561.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regrappod--february-2024/562.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/commentary/cell-and-gene-therapy-rare-disease-drug-development-in-the-us-general-principles-challenges-and-a-landscape-of-mutual-regulatory-concession/563.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/angioedemas-caused-by-rare-gene-fault-curable-by-crispr/565.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/violin-resin-works-as-cleaning-agent-for-superbugs/566.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-reclassifies-codeine-linctus-as-prescription-only/582.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/pharmaceuticals/can-the-japanese-phase-i-study-be-waived/572.article 2024-03-07T16:57:40.437Z https://www.regulatoryrapporteur.org/pharmaceuticals/navigating-the-regulatory-terrain-down-under-trends-in-australia-for-2024/573.article 2024-03-07T16:57:10.187Z https://www.regulatoryrapporteur.org/pharmaceuticals/clinical-trial-design-keeping-up-with-innovation/574.article 2024-03-26T16:12:01.987Z https://www.regulatoryrapporteur.org/pharmaceuticals/regulatory-imperatives-in-chemistry-manufacturing-and-control-for-biosimilars-a-comprehensive-analysis/575.article 2024-04-23T13:52:37.660Z https://www.regulatoryrapporteur.org/veterinary/new-data-protection-for-maximum-residue-limits/576.article 2024-03-07T16:52:17.800Z https://www.regulatoryrapporteur.org/editorials/diverse-and-dynamic-regulation-in-the-asia-pacific-region/577.article 2024-04-30T14:56:01.697Z https://www.regulatoryrapporteur.org/march-2024-contents/578.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/pharmaceuticals/overview-of-digital-transformation-in-healthcare-and-initiatives-in-japan/580.article 2024-03-14T16:44:34.520Z https://www.regulatoryrapporteur.org/industry-news/sponge-on-a-string-cuts-wait-time-for-barretts-diagnosis/590.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/radio-waves-used-to-hijack-ecoli-bacteria-to-make-medicines/591.article 2024-04-09T16:16:44.423Z https://www.regulatoryrapporteur.org/industry-news/cholera-vaccine-shortage-puts-millions-at-risk/607.article 2024-05-20T08:30:53.080Z https://www.regulatoryrapporteur.org/editorials/improving-outcomes-with-data/579.article 2025-02-06T16:35:18.240Z https://www.regulatoryrapporteur.org/product-information/navigating-the-future-of-medicinal-product-data-exchange-understanding-xevmpd/597.article 2024-04-23T14:22:03.453Z https://www.regulatoryrapporteur.org/data-quality-governance-and-sharing-to-enable-insights-and-decision-making/598.article 2024-04-16T11:17:29.407Z https://www.regulatoryrapporteur.org/medical-devices/device-submissions-for-combination-products-a-data-driven-perspective/600.article 2024-04-22T08:23:05.070Z https://www.regulatoryrapporteur.org/pharmaceuticals/choosing-the-right-registration-pathway-for-the-china-drug-master-file-an-essential-analysis-of-options/601.article 2024-04-16T11:17:15.490Z https://www.regulatoryrapporteur.org/pharmaceuticals/managing-risks-successful-clinical-development-in-asthma/602.article 2024-04-16T11:17:05.047Z https://www.regulatoryrapporteur.org/pharmaceuticals/unveiling-the-synergy-of-ais-regulatory-harmony-in-shaping-the-future-of-biopharmaceutical-progress/605.article 2024-05-20T09:46:37.057Z https://www.regulatoryrapporteur.org/industry-news/utah-law-to-permit-non-fda-approved-stem-cell-therapies/609.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/april-2024-contents/603.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/cutting-antibiotic-usage-reduces-resistance-levels/611.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/podcasts/regrappod--april-2024/612.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/modified-skin-bacteria-treats-tumours-in-mice/616.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/novel-antibiotic-receives-emas-recommendation/617.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/parkinsons-drug-slows-progression-of-motor-symptoms/618.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/industry-news/dr-congo-mining-town-sees-novel-monkeypox-strain/636.article 2024-06-14T14:11:26.600Z https://www.regulatoryrapporteur.org/podcasts/regrappod--in-conversation-with-helena-corte-real/631.article 2025-02-06T14:13:56.183Z https://www.regulatoryrapporteur.org/dr-peter-marks-on-reflecting-innovation-through-fda-regulation/623.article 2025-06-02T14:01:27.090Z https://www.regulatoryrapporteur.org/may-2024-contents/620.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/navigating-the-process-complexities-and-challenges-associated-with-eu-ctr-transition-applications/622.article 2024-05-17T09:07:59.337Z https://www.regulatoryrapporteur.org/pharmaceuticals/near-term-challenges-of-advanced-therapy-medicinal-products-a-maturing-product-class/624.article 2024-05-17T09:07:37.183Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-first-approval-of-a-crispr-cas9-gene-editing-medicinal-product-in-the-european-union-casgevy/619.article 2024-05-17T09:07:31.040Z https://www.regulatoryrapporteur.org/editorials/unlocking-a-new-paradigm-of-healthcare-through-advanced-therapies/625.article 2024-05-08T14:59:43.313Z https://www.regulatoryrapporteur.org/medical-devices/the-european-association-of-authorised-representatives/627.article 2024-06-19T10:37:10.330Z https://www.regulatoryrapporteur.org/cell-gene-therapy-clinical-trial-application-procedure-of-car-t-therapy-in-the-eu/628.article 2024-05-17T09:07:42.620Z https://www.regulatoryrapporteur.org/medical-devices/medical-device-standards-update-march-2024/632.article 2024-12-02T10:17:53.467Z https://www.regulatoryrapporteur.org/podcasts/regrappod--may-2024/633.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/melanoma-vaccine-enters-phase-iii-clinical-trials/637.article 2024-05-14T13:22:34.327Z https://www.regulatoryrapporteur.org/sign-up-to-regulatory-rapporteur-and-get-more-content/638.article 2024-05-16T10:38:40.600Z https://www.regulatoryrapporteur.org/industry-news/astrazeneca-set-to-withdraw-its-covid-19-vaccine/639.article 2025-11-25T14:53:00.690Z https://www.regulatoryrapporteur.org/industry-news/unchecked-amr-could-make-covid-19-pandemic-minor/642.article 2024-06-03T08:37:53.110Z https://www.regulatoryrapporteur.org/podcasts/regrappod--in-conversation-with-bengt-mattson/645.article 2025-02-06T14:12:12.763Z https://www.regulatoryrapporteur.org/industry-news/fda-programme-set-to-improve-diversity-in-clinical-trials/647.article 2026-02-05T12:07:54.193Z https://www.regulatoryrapporteur.org/pharmaceuticals/june-2024-contents/648.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/pharmaceuticals/comparing-china-drug-master-files-with-the-eu-and-us/650.article 2024-09-13T08:50:24.103Z https://www.regulatoryrapporteur.org/pharmaceuticals/opportunities-and-challenges-in-the-latin-american-pharmaceutical-industry/652.article 2024-07-04T09:47:54.590Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-availability-of-medicines-post-brexit-in-malta/653.article 2024-12-06T12:09:23.990Z https://www.regulatoryrapporteur.org/pharmaceuticals/project-orbis-a-sponsors-perspective-on-the-collaborative-international-review-process/654.article 2024-08-29T12:31:22.023Z https://www.regulatoryrapporteur.org/veterinary/over-two-years-into-the-new-veterinary-medicines-rules-for-the-eu-a-reflection-on-where-we-are-now/655.article 2024-07-02T09:40:26.337Z https://www.regulatoryrapporteur.org/medical-devices/the-uk-responsible-person-association/656.article 2024-07-02T09:39:52.970Z https://www.regulatoryrapporteur.org/editorials/the-global-access-battle-for-healthcare-equity/673.article 2024-08-13T08:27:04.320Z https://www.regulatoryrapporteur.org/industry-news/first-human-death-from-h5n2-avian-flu-recorded-in-mexico/674.article 2024-06-14T08:26:00.567Z https://www.regulatoryrapporteur.org/industry-news/ai-used-to-predict-candidate-antibiotics-in-radical-study/675.article 2024-09-16T13:41:52.617Z https://www.regulatoryrapporteur.org/a-key-role-for-the-european-medicines-agency-in-the-european-unions-health-technology-assessment-regulation/676.article 2026-04-07T14:57:26.300Z https://www.regulatoryrapporteur.org/industry-news/who-issues-global-warning-on-fake-ozempic-medication/681.article 2024-06-25T14:38:47.983Z https://www.regulatoryrapporteur.org/podcasts/regrappod--june-2024/683.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/industry-news/critical-need-to-address-mpox-strain-says-who/697.article 2024-07-03T09:14:30.150Z https://www.regulatoryrapporteur.org/gene-therapy-restores-hearing-in-five-children/698.article 2024-07-12T14:49:03.193Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-sustainability-imperative-for-the-healthcare-sector/702.article 2024-08-29T15:48:33.573Z https://www.regulatoryrapporteur.org/regulatory-procedures/green-claims-related-to-animal-feed-products-in-the-eu-substantiation-labelling-and-regulatory-developments/699.article 2024-09-23T10:44:27.690Z https://www.regulatoryrapporteur.org/pharmaceuticals/what-is-involved-in-the-role-of-the-person-responsible-for-regulatory-compliance-prrc/701.article 2024-08-29T15:55:40.783Z https://www.regulatoryrapporteur.org/pharmaceuticals/e-labelling-revolutionising-the-labelling-landscape/707.article 2025-04-07T16:40:11.613Z https://www.regulatoryrapporteur.org/pharmaceuticals/new-approach-methodologies-for-the-biological-safety-assessment-of-medical-devices/708.article 2024-08-30T11:41:11.463Z https://www.regulatoryrapporteur.org/ema-revises-the-guideline-for-environmental-risk-assessment-of-medicinal-products-for-human-use/709.article 2024-09-13T09:06:49.003Z https://www.regulatoryrapporteur.org/main-navigation/sustainable-design-and-manufacture-in-medical-devices/714.article 2024-08-30T08:25:45.700Z https://www.regulatoryrapporteur.org/main-navigation/uk-epi-task-force-evidence-review-electronic-patient-information-leaflets-epils/716.article 2025-04-07T16:40:15.053Z https://www.regulatoryrapporteur.org/july/august-2024-contents/717.article 2025-01-27T10:39:35.547Z https://www.regulatoryrapporteur.org/interviews/bengt-mattson-reflects-on-sustainability/711.article 2024-11-12T16:12:53.587Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-relevance-of-sustainability-in-regulatory-affairs-consultancies/684.article 2024-08-30T11:57:14.040Z https://www.regulatoryrapporteur.org/editorials/sustainable-pharmaceuticals/720.article 2024-09-12T18:07:46.590Z https://www.regulatoryrapporteur.org/september-2024-contents/742.article 2024-12-06T12:17:15.017Z https://www.regulatoryrapporteur.org/editorials/the-complexities-of-botanical-regulation/743.article 2024-10-08T15:56:23.607Z https://www.regulatoryrapporteur.org/biologics/botanicals-and-digestive-enzymes-demonstrate-the-complexity-and-diversity-of-food-supplement-regulations-in-the-european-union/730.article 2024-11-29T14:27:39.400Z https://www.regulatoryrapporteur.org/software/borderline-products-and-self-care-in-the-digital-age/729.article 2024-09-16T09:31:01.040Z https://www.regulatoryrapporteur.org/biologics/introduction-to-cannabinoids-understanding-uk-regulation-structure-industry-dynamics-and-charting-the-future/736.article 2024-09-13T12:16:12.080Z https://www.regulatoryrapporteur.org/regulatory-procedures/navigating-drug-registration-in-china-accelerated-review-policies-and-pathways/725.article 2024-09-13T12:17:26.150Z https://www.regulatoryrapporteur.org/what-are-the-future-prospects-for-antimicrobial-agents/728.article 2026-03-04T17:20:47.160Z https://www.regulatoryrapporteur.org/regulatory-procedures/sustainability-and-personal-care-a-regulatory-view/732.article 2024-09-13T12:18:12.360Z https://www.regulatoryrapporteur.org/industry-news/nice-and-ema-say-new-alzheimers-drug-is-not-recommended/734.article 2024-09-19T13:44:09.600Z https://www.regulatoryrapporteur.org/industry-news/uk-pledges-to-join-the-trans-pacific-partnership-by-end-of-2024/740.article 2024-09-19T08:29:54.327Z https://www.regulatoryrapporteur.org/industry-news/contraindication-for-mixing-weight-loss-medicine-mysimba-with-opioids/738.article 2024-11-12T10:52:56.603Z https://www.regulatoryrapporteur.org/industry-news/who-issues-warning-on-fake-opioids-in-europe/741.article 2024-12-13T10:15:06.970Z https://www.regulatoryrapporteur.org/industry-news/new-editor-in-chief-for-regulatory-rapporteur/750.article 2025-09-09T14:08:50.830Z https://www.regulatoryrapporteur.org/october-2024-contents/756.article 2024-12-06T12:16:49.703Z https://www.regulatoryrapporteur.org/cmc-regulatory-considerations-for-paediatric-formulation-development/751.article 2024-11-04T09:55:15.150Z https://www.regulatoryrapporteur.org/artificial-intelligence/breaking-barriers-the-future-of-cmc-powered-by-ai/752.article 2025-12-11T18:29:50.470Z https://www.regulatoryrapporteur.org/regulatory-procedures/revolutionising-compliance-with-dadi-a-new-frontier-for-digital-integration/753.article 2024-11-26T08:58:13.980Z https://www.regulatoryrapporteur.org/atmp/small-interfering-rna-regulatory-challenges-and-therapeutic-potential/754.article 2024-10-11T10:25:10.893Z https://www.regulatoryrapporteur.org/regulatory-procedures/a-comparative-analysis-between-ich-q2r2-and-ich-q14/757.article 2025-12-11T18:30:03.780Z https://www.regulatoryrapporteur.org/editorials/chemistry-manufacturing-and-controls-accelerating-development-and-boosting-innovation/755.article 2024-10-11T14:11:30.710Z https://www.regulatoryrapporteur.org/streamline-medical-device-compliance-with-bsi-compliance-navigator/726.article 2025-08-13T09:05:31.720Z https://www.regulatoryrapporteur.org/industry-news/regulators-publish-new-guidelines-for-use-of-ai/758.article 2024-10-24T12:02:03.670Z https://www.regulatoryrapporteur.org/industry-news/who-pandemic-agreement-gains-signatories/759.article 2024-11-15T15:33:46.643Z https://www.regulatoryrapporteur.org/editorials/improving-health-outcomes-through-regulatory-excellence/773.article 2024-11-08T06:54:59.110Z https://www.regulatoryrapporteur.org/november-2024-contents-human-medicines-sessions/785.article 2024-12-06T15:13:34.690Z https://www.regulatoryrapporteur.org/medical-devices/november-2024-contents-medical-devices/ivds-sessions/788.article 2024-12-06T12:14:17.873Z https://www.regulatoryrapporteur.org/november-2024-contents-veterinary-medicines-sessions/789.article 2024-12-06T12:16:25.373Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm2-european-clinical-research-ecosystem-how-to-boost-its-competitiveness/762.article 2024-12-23T16:43:39.390Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm4-electronic-product-information-epi-a-digital-passport-for-medicinal-product-information/765.article 2025-04-07T16:40:10.020Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm3-regulation-and-innovation-keeping-up-with-the-times-fireside-chat/766.article 2025-11-11T10:01:12.270Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm1-ensuring-regulatory-excellence/767.article 2025-08-15T11:34:01.073Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm7-clinical-evidence-generation-in-europe-is-it-time-for-a-more-holistic-view-of-global-healthcare-product-development/763.article 2024-12-23T16:53:37.837Z https://www.regulatoryrapporteur.org/medical-devices/hm5/md1/ivd1-combine-project-a-new-era-of-combined-clinical-trials-in-europe/768.article 2024-12-23T16:49:11.093Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm6-artificial-intelligence-how-will-ai-and-machine-learning-tools-transform-regulatory-practice/777.article 2024-12-23T16:50:36.747Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm8-how-the-new-eu-regulation-on-health-technology-assessment-hta-will-change-clinical-drug-development-and-regulatory-affairs/761.article 2026-04-07T14:57:24.790Z https://www.regulatoryrapporteur.org/pharmaceuticals/hm9-clinical-trial-applications-eu-clinical-trial-regulation-and-beyond/781.article 2024-12-23T16:58:01.677Z https://www.regulatoryrapporteur.org/regulatory-procedures/ps1-resolving-specific-development-hurdles-via-scientific-advice/782.article 2024-12-24T09:07:37.050Z https://www.regulatoryrapporteur.org/regulatory-procedures/sme-regulatory-updates-for-sme-academia-and-start-ups/786.article 2024-12-24T09:11:51.707Z https://www.regulatoryrapporteur.org/pharmaceuticals/topra-annual-lecture-status-of-global-health/787.article 2024-11-11T09:16:33.430Z https://www.regulatoryrapporteur.org/artificial-intelligence/md2/ivd2-unravelling-ai-as-a-medical-device-insights-into-the-eu-ai-act-and-other-global-perspectives/769.article 2024-12-23T17:00:06.617Z https://www.regulatoryrapporteur.org/medical-devices/md3/ivd3-the-impact-of-mdr/ivdr-and-its-effect-on-future-developments-of-policies-manufacturers-and-inspectorates/771.article 2024-12-23T17:02:19.060Z https://www.regulatoryrapporteur.org/regulatory-procedures/ps2-patient-experience-data-the-next-steps-towards-medicines-evaluation/783.article 2024-12-24T09:09:32.323Z https://www.regulatoryrapporteur.org/medical-devices/md4/ivd4-uk-mdr-current-requirements-and-future-perspectives-for-medical-devices-and-in-vitro-diagnostics/784.article 2024-12-23T17:03:43.897Z https://www.regulatoryrapporteur.org/medical-devices/md5/ivd5-responsible-and-experienced-prrcs-for-mdr-and-ivdr/770.article 2024-12-23T17:05:17.610Z https://www.regulatoryrapporteur.org/veterinary/vm2-progress-in-veterinary-regulatory-procedures-opportunities-and-threats-concerning-the-implementation-of-regulation-eu-2019/6/772.article 2025-06-18T17:01:08.017Z https://www.regulatoryrapporteur.org/veterinary/vm1-advancing-regulatory-policies-for-one-health-a-holistic-approach-to-animal-and-public-health/774.article 2025-06-18T17:01:01.323Z https://www.regulatoryrapporteur.org/veterinary/vm3-navigating-the-regulatory-landscape-of-veterinary-product-information/775.article 2025-06-18T17:01:09.510Z https://www.regulatoryrapporteur.org/veterinary/vm4-advancing-veterinary-pharmacovigilance-insights-into-signal-management-first-experiences-with-phv-inspections-and-introducing-the-ema-adr-data-quality-framework/779.article 2025-06-18T17:00:58.693Z https://www.regulatoryrapporteur.org/veterinary/vm5-exploring-the-future-of-veterinary-regulatory-affairs-harnessing-science-and-innovation-for-animal-health-excellence/780.article 2025-06-18T17:01:00.313Z https://www.regulatoryrapporteur.org/industry-news/new-guidance-for-wholesalers-and-manufacturers-following-windsor-framework/790.article 2024-11-21T15:39:43.417Z https://www.regulatoryrapporteur.org/industry-news/new-cancer-drug-approved-by-mhra/791.article 2024-11-21T17:28:03.817Z https://www.regulatoryrapporteur.org/industry-news/fda-proposes-to-remove-oral-phenylephrine-in-selected-drugs/792.article 2025-02-05T12:34:02.833Z https://www.regulatoryrapporteur.org/industry-news/greater-post-market-surveillance-for-medical-devices/793.article 2024-11-21T17:28:19.017Z https://www.regulatoryrapporteur.org/editorials/north-america-navigating-key-regulatory-updates/800.article 2025-01-08T16:03:39.863Z https://www.regulatoryrapporteur.org/december-2024-contents/803.article 2025-01-08T18:21:10.620Z https://www.regulatoryrapporteur.org/regulatory-procedures/health-canada-points-to-consider-when-preparing-quality-and-new-substance-notification-documentation-for-investigational-medicinal-products/795.article 2024-12-06T14:46:16.087Z https://www.regulatoryrapporteur.org/regulatory-procedures/notable-us-food-and-drug-administration-pilot-programmes/796.article 2024-12-06T14:33:50.190Z https://www.regulatoryrapporteur.org/regulatory-procedures/shedding-light-on-essential-drug-delivery-outputs/799.article 2024-12-06T15:11:37.863Z https://www.regulatoryrapporteur.org/medical-devices/medical-device-standards-update-december-2024/802.article 2025-01-08T17:18:37.350Z https://www.regulatoryrapporteur.org/regulatory-procedures/transitioning-to-the-clinical-trials-regulation-the-roche-experience/794.article 2024-12-06T11:55:23.653Z https://www.regulatoryrapporteur.org/regulatory-procedures/early-development-of-vaccines-and-prophylactics-in-infectious-diseases-a-post-pandemic-regulatory-overview/797.article 2024-12-06T11:55:38.747Z https://www.regulatoryrapporteur.org/pharmaceuticals/november-2024-contents/805.article 2025-11-17T15:14:43.460Z https://www.regulatoryrapporteur.org/industry-news/gsk-blenrep-trial-shows-significant-overall-survival-benefitof-myeloma-treatment/808.article 2024-12-13T11:10:03.730Z https://www.regulatoryrapporteur.org/industry-news/increased-debate-over-lecanemab/806.article 2024-12-13T11:17:05.333Z https://www.regulatoryrapporteur.org/industry-news/use-of-new-ema-platform-for-monitoring-medicine-shortages-to-become-mandatory/809.article 2024-12-13T11:21:43.270Z